FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011483771> ?p ?o ?g. }

• W2011483771 endingPage "b3922" @default.
• W2011483771 startingPage "b3922" @default.
• W2011483771 abstract "<h3>Objective:</h3> To investigate changes in brain temperature (T_CRE) in patients with treatment resistant epilepsy (TRE) who receive Cannabidiol (CBD). <h3>Background:</h3> CBD’s efficacy in TRE may stem from targeting neuroinflammation. Brain temperature elevations (T_CRE=−102.61(Δ_H20−CRE)+206.1°C) may be considered a proxy for neuroinflammation and can be non-invasively mapped using magnetic resonance spectroscopic imaging and thermometry (MRSI-t). Although MRSI-t studies have documented T_CRE elevations in TRE patients’ seizure onset zones (SOZs), no study has investigated if T_CRE are affected by a treatment that has anti-inflammatory effects (CBD). <h3>Design/Methods:</h3> Five adults aged 20 – 43 years (3 females) with TRE were imaged at 3T before (baseline) and after 12-weeks of CBD (on-CBD). Data were processed within the Metabolite Imaging and Data Analysis System software package. Voxelwise brain temperature calculations generated 3D T_CRE maps; voxelwise subtraction maps visualized each participants’ baseline vs. on-CBD T_CRE changes. Mean T_CRE was also estimated for 47 atlas-defined brain regions and evaluated using repeated measures t-tests. The Chalfont Seizure Severity Scale (CSSS) evaluated CBD efficacy and medical records provided seizure frequency. Mood was assessed using the Total Mood Disturbance (TMD) score on the Profile of Mood States (POMS). Repeated measures t-tests computed changes in seizure symptoms and mood. <h3>Results:</h3> Baseline T_CRE elevations (>37.5°C) were localized to clinically implicated seizure generation and/or propagation sites. All participants’ seizure severity (<i>p</i>=0.015) and brain temperature (<i>p</i><0.0001) decreased from baseline to on-CBD. There was also a non-significant decrease in POMS TMD. <h3>Conclusions:</h3> MRSI-t documented T_CRE decreases in patients treated with CBD for treatment-resistant epilepsy. The observed effects may be related to CBD exposure, decreased seizure frequency/severity, or both. T_CRE derived from MRSI-t may be a promising imaging-based biomarker for tracking neuroinflammation in patients with neurological conditions including epilepsy. Future findings from this on-going study will provide critical insights into CBD’s effects in the human brain. <b>Disclosure:</b> Mrs. Sharma has nothing to disclose. Dr. Szaflarski has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for SK Life Sciences. Dr. Szaflarski has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for LivaNova Inc. Dr. Szaflarski has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Serina Therapeutics. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GW Biosciences. An immediate family member of Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GW Biosciences. Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firm. Dr. Szaflarski has stock in AdCel Biopharma, LLC. Dr. Szaflarski has stock in iFovea." @default.
• W2011483771 created "2016-06-24" @default.
• W2011483771 creator A5030853287 @default.
• W2011483771 date "2009-09-29" @default.
• W2011483771 modified "2023-09-23" @default.
• W2011483771 title "Improving the use of IT in the NHS" @default.
• W2011483771 doi "https://doi.org/10.1136/bmj.b3922" @default.
• W2011483771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19808830" @default.
• W2011483771 hasPublicationYear "2009" @default.
• W2011483771 type Work @default.
• W2011483771 sameAs 2011483771 @default.
• W2011483771 citedByCount "1" @default.
• W2011483771 crossrefType "journal-article" @default.
• W2011483771 hasAuthorship W2011483771A5030853287 @default.
• W2011483771 hasConcept C118552586 @default.
• W2011483771 hasConcept C126322002 @default.
• W2011483771 hasConcept C126838900 @default.
• W2011483771 hasConcept C143409427 @default.
• W2011483771 hasConcept C15744967 @default.
• W2011483771 hasConcept C2777134132 @default.
• W2011483771 hasConcept C2778186239 @default.
• W2011483771 hasConcept C2780733359 @default.
• W2011483771 hasConcept C2989005 @default.
• W2011483771 hasConcept C558461103 @default.
• W2011483771 hasConcept C71924100 @default.
• W2011483771 hasConceptScore W2011483771C118552586 @default.
• W2011483771 hasConceptScore W2011483771C126322002 @default.
• W2011483771 hasConceptScore W2011483771C126838900 @default.
• W2011483771 hasConceptScore W2011483771C143409427 @default.
• W2011483771 hasConceptScore W2011483771C15744967 @default.
• W2011483771 hasConceptScore W2011483771C2777134132 @default.
• W2011483771 hasConceptScore W2011483771C2778186239 @default.
• W2011483771 hasConceptScore W2011483771C2780733359 @default.
• W2011483771 hasConceptScore W2011483771C2989005 @default.
• W2011483771 hasConceptScore W2011483771C558461103 @default.
• W2011483771 hasConceptScore W2011483771C71924100 @default.
• W2011483771 hasIssue "sep29 2" @default.
• W2011483771 hasLocation W20114837711 @default.
• W2011483771 hasLocation W20114837712 @default.
• W2011483771 hasOpenAccess W2011483771 @default.
• W2011483771 hasPrimaryLocation W20114837711 @default.
• W2011483771 hasRelatedWork W1977098177 @default.
• W2011483771 hasRelatedWork W2004025092 @default.
• W2011483771 hasRelatedWork W2019944782 @default.
• W2011483771 hasRelatedWork W2053874771 @default.
• W2011483771 hasRelatedWork W2064318755 @default.
• W2011483771 hasRelatedWork W2077319519 @default.
• W2011483771 hasRelatedWork W2121844130 @default.
• W2011483771 hasRelatedWork W2748952813 @default.
• W2011483771 hasRelatedWork W2811302506 @default.
• W2011483771 hasRelatedWork W2899084033 @default.
• W2011483771 hasVolume "339" @default.
• W2011483771 isParatext "false" @default.
• W2011483771 isRetracted "false" @default.
• W2011483771 magId "2011483771" @default.
• W2011483771 workType "article" @default.